Clinical Studies

References, By Product.

At The Gut Co., we want to help you make healthy choices, and those choices start with understanding the ingredients in your supplements.

We combed through the most important and trusted clinical studies in the gut health space in order to create supplements that contain the EXACT ingredients proven to be most effective in EXACTLY the right doses.

Please find our references for each product below.

Gut Care Studies

Actazin®

4 Ansel et al. (2015) - Kiwifruit-derived supplements increase stool frequency in healthy adults: a randomized, double-blind, placebo-controlled study - Nutrition Research

This study demonstrated that Actazin produced clinically meaningful increases in bowel movements in healthy individuals. Consumption of Actazin significantly increased the number of daily bowel movements by greater than 1 bowel movement per week.

5 Blatchford et al. (2017) - Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial - Journal of Nutritional Science

This study found that the abundance of Faecalibacterium prausnitzii, a beneficial microbe, significantly increased following kiwifruit capsule supplementation by 3.4 to 7%.

Wang et al. (2018) - Bioactive Compounds and in vitro antioxidant activities of peel, flesh, and seed powder of kiwi fruit - Institute of Food Science and Technology.

This study found that the compounds of kiwifruit make for promising ingredients for use in the enrichment of products providing dietary fibre, bioactive compounds, and antioxidant action.

Actinidin

J. Agric. Et al. (2010) - Actinidin Enhances Protein Digestion in the Small Intestine As Assessed Using an in Vitro Digestion Model - American Chemical Society.

This study found that kiwifruit influenced the digestion patterns of all of the proteins in the small intestine.

Saccharomyces Boulardii

5 6 McFarland, L. (2010) - Systematic review and meta-analysis of Saccharomyces boulardii in adult patients - World Journal of Gastroenterology.

In adults, Saccharomyces Boulardii, a beneficial yeast, can be strongly recommended for the prevention of antibiotic-associated diarrhea and traveller’s diarrhea. This study also supports the use of this yeast probiotic for the prevention of enteral nutrition-related diarrhea and reduction of Helicobacter pylori treatment-related symptoms. S.Boulardii is also showing promise for helping to prevent IBS and acute diarrhea. Of 31 randomized, placebo-controlled treatment arms in 27 trials (encompassing 5029 study patients), S. boulardii was found to be significantly efficacious and safe in 84% of those treatment arms.

Czerucka et al. (2007) - Review article: Yeast as probiotics - Saccharomyces boulardii - Aliment Pharmacol Ther.

An earlier study outlining promising research perspectives being opened in terms of maintenance treatment of inflammatory bowel diseases. Experimental studies clearly demonstrate the probiotic properties of Saccharomyces boulardii, opening the door for new therapeutic uses of this yeast as an ‘immunobiotic’.

Guslandi et al. (2000) - Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease - Digestive Disease and Sciences.

Results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn’s Disease. Thirty-two patients with Crohn's disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent.

Sivananthan et al. (2018) - Review of Saccharomyces boulardii as a treatment option in IBD - Immunopharmacology and Immunotoxicology.

Three clinical trials showed a positive effect of S.boulardii in IBD patients (two Crohn’s disease and one ulcerative colitis). Some animal trials and cell assays describe different anti-inflammatory mechanisms of S.boulardii supporting a possible effect when treating IBD patients.

Synbio®

1 Silvie et al. (2014) - Probiotic-enriched foods and dietary supplement containing SYNBIO positively affects bowel habits in healthy adults: an assessment using standard statistical analysis and Support Vector Machines - International Journal of Food Sciences & Nutrition.

Synbio consumption improved bowel habits of volunteers consuming the probiotic foods or capsules. The recovery of probiotic bacteria from the faeces of a cohort of 100 subjects for each supplemented group showed the persistence of strains in the gastrointestinal tract.

2 Coman et al. (2014) - In vitro evaluation of antimicrobial activity of Lactobacillus rhamnosus IMC 501®, Lactobacillus paracasei IMC 502 and SYNBIO against pathogens - Journal of Applied Microbiology.

These probiotics have great potential to produce antimicrobial compounds that inhibit and control the microbial pathogen growth. These probiotic strains may prove useful in the adjunct treatment with probiotics in cure of different gastrointestinal infections.

3 Coman et al. (2014) - Functional foods as carriers for SYNBIO®, a probiotic bacteria combination - International Food Journal of Microbiology.

The aim of this study was to develop new probiotic food products that include a dose of Synbio. The food products outlined in this study (a mix of dairy and non-dairy) would be excellent vehicles to deliver probiotic health effects because of the high viability of probiotics during the shelf-life of foods and in some cases even after their expiry date.

Verdenelli et al. (2011) - Influence of a combination of two potential probiotic strains, Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502 on bowel habits of healthy adults - Letters in Applied Microbiology.

Daily consumption of food products enriched with the two potential probiotic strains, Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502, contributes to improve intestinal microbiota with beneficial properties and enhances bowel habits of healthy adults. After the intervention, a significant increase in faecal lactobacilli and bifidobacteria were observed in the probiotic group, and stool frequency and stool volume were higher in the probiotic group than in the placebo group.

L. Rhamnosus IMC / Lactobacillus Rhamnosus / L. Paracasei

Segers et al. (2014) - Towards a better understanding of Lactobacillus rhamnosus GG - Microbial Cell Factories.

Lactobacillus rhamnosus is one of the most widely used probiotic strains. Various health effects are well documented including the prevention and treatment of gastro-intestinal infections and diarrhea, and stimulation of immune responses that promote vaccination or even prevent certain allergic symptoms.

Szajewska et al. (2015) - Systematic review with meta-analysis: Lactobacillus rhamnosus in the prevention of antibiotic-associated diarrhoea in children and adults - Alimentary Pharmacology & Therapeutics.

A review of 12 studies in 1,499 people found that supplementing with L. rhamnosus reduced the risk of antibiotic-related diarrhoea from 22.4% to 12.3%.

Francavilla et al. (2010) - A randomized controlled trial of Lactobacillus in children with functional abdominal pain - Pediatrics.

Lactobacillus-rich foods and supplements have been shown to possibly relieve common IBS symptoms, such as abdominal pain.

Yan et al. (2012) - Lactobacillus rhamnosus: An Updated Strategy to Use Microbial Products to Promote Health - The Journal of Functional Foods.

This strain is better adapted to survive in acidic and basic conditions within your body and can adhere to and colonize your intestinal walls. Such traits give L. rhamnosus a better chance of survival, offering longer-term health benefits.

Verdenelli et al. (2009) - Probiotic properties of Lactobacillus rhamnosus and Lactobacillus paracasei isolated from human faeces - European Journal of Nutrition.

In antimicrobial activity assays, both strains showed inhibitory properties towards selected potential harmful microorganisms, particularly against candida albicans.